Are Price Controls Secretly Costing Your Health Innovation?

Real-World Examples and Data

Countries with stringent price control measures, such as Canada and parts of Europe, often experience delays in the availability of new drugs compared to the United States². For instance, a report by the Fraser Institute found that Canadians wait longer for new medicines, with only 47% of new drugs launched globally between 2011 and 2018 being available in Canada by 2018³. This delay can be attributed to the lower profit potential under price controls, which discourages companies from launching new products in these markets.